Stockscreener 앱 받기
9.00
3.33%
-0.31
전일 마감가:
$9.31
열려 있는:
$9.3
하루 거래량:
43,492
Relative Volume:
0.07
시가총액:
$20.54M
수익:
$1.47M
순이익/손실:
$-97.61M
주가수익비율:
-6.0403
EPS:
-1.49
순현금흐름:
$-80.90M
1주 성능:
-32.74%
1개월 성능:
-67.37%
6개월 성능:
-13.46%
1년 성능:
-35.71%
1일 변동 폭
$8.8633
$9.30
1주일 범위
$8.35
$9.9487
52주 변동 폭
$3.8101
$37.50
Lyra Therapeutics Inc Stock (LYRA) Company Profile
명칭
Lyra Therapeutics Inc
전화
617-373-4600
주소
480 ARSENAL WAY, WATERTOWN, MA
LYRA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LYRA
Lyra Therapeutics Inc
|
9.00 | 20.54M | 1.47M | -97.61M | -80.90M | -1.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-07 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2024-05-07 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-05-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-05-06 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-06 | 재개 | BTIG Research | Buy |
| 2023-08-31 | 개시 | H.C. Wainwright | Buy |
| 2022-05-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-05-26 | 개시 | BTIG Research | Buy |
| 2020-05-26 | 개시 | BofA/Merrill | Buy |
| 2020-05-26 | 개시 | Jefferies | Buy |
| 2020-05-26 | 개시 | William Blair | Outperform |
모두보기
Lyra Therapeutics Inc 주식(LYRA)의 최신 뉴스
Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst - Seeking Alpha
Lyra Therapeutics, Inc. (NASDAQ:LYRA) Stake Lessened by Two Sigma Investments LP - Defense World
HC Wainwright Expects Higher Earnings for Lyra Therapeutics - Defense World
Lyra Therapeutics (LYRA) Upgraded to Buy: Here's Why - sharewise
H.C. Wainwright lifts Lyra Therapeutics stock target to $16 By Investing.com - Investing.com Canada
Lyra Therapeutics (LYRA) Price Target Raised by HC Wainwright & Co. | LYRA Stock News - GuruFocus
H.C. Wainwright Ups Target Price for Lyra Therapeutics (LYRA) to $16 | LYRA Stock News - GuruFocus
Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Sold by Two Sigma Advisers LP - Defense World
Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success - MSN
Lyra Eyes US Filing For LYR-210 After Surprise ENLIGHTEN 2 Win - insights.citeline.com
Northern Trust Corp Has $59,000 Stock Position in Lyra Therapeutics, Inc. (NASDAQ:LYRA) - Defense World
Study: LYR-210 Shows Promise in Chronic Rhinosinusitis With Nasal Polyps - Pharmacy Times
BNP Paribas Financial Markets Makes New Investment in Lyra Therapeutics, Inc. (NASDAQ:LYRA) - Defense World
Best Biotech Stocks To Watch Now – June 2nd - Defense World
Biotech Triumphs: Lyra, Vera, And US Gold Shine Bright - Finimize
Lyra Therapeutics stock hits 52-week high at $28.66 By Investing.com - Investing.com Canada
Lyra Therapeutics Stock Skyrockets On Positive Trial Data For Its Nasal Implant: Retail’s Thrilled - Asianet Newsable
Lyra Therapeutics reports positive phase 3 trial results for CRS treatment By Investing.com - Investing.com South Africa
Applied Digital Corp, Meta Platforms, Alphabet, Lyra Therapeutics, Tesla: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Lyra Therapeutics Stock Skyrockets On Positive Trial Data For Its Nasal Implant: Retail’s Thrilled By Stocktwits - Investing.com India
Redemption for Lyra as second phase III rhinosinusitis trial hits goal - BioWorld MedTech
One year after massive layoffs, Lyra stock soars 400% on trial win - The Business Journals
Lyra Therapeutics (LYRA) Surges 376% on Positive Phase 3 Trial R - GuruFocus
Lyra Therapeutics (LYRA) Surges 376% on Positive Phase 3 Trial Results - GuruFocus
Microcap Lyra Therapeutics surges 376% on phase 3 rhinosinusitis data - Seeking Alpha
Nasdaq Edges Higher; ISM Manufacturing PMI Falls In May - Benzinga
Lyra Therapeutics Shares Climb Over 500% After Major CRS Trial Win - Yahoo Finance
Lyra Therapeutics Spikes 417% as LYR-210 Redefines CRS Therapy - Wall Street Pit
LYR-210 Nasal Implant for CRS Brings Symptom Relief in Phase 3 ENLIGHTEN 2 - HCPLive
Lyra Therapeutics says ENLIGHTEN 2 trial of LYR-210 met primary endpoint - TipRanks
Lyra Therapeutics Soars on Breakthrough Nasal Implant Results - RagingBull
Lyra Therapeutics Shares Soar 603.25% to $34.67 on LYR-210 Trial Success - Trading Pedia
Transcript : Lyra Therapeutics, Inc.Special Call - marketscreener.com
Lyra Therapeutics stock hits 52-week high at $28.66 - Investing.com
This penny stock just spiked 550% in a day; Time to buy? - Finbold
Lyra Therapeutics Stock (LYRA) Rockets 530% on Phase 3 Trial Results - TipRanks
Pre-market Movers: LYRA, INM, OGEN, VERA... - RTTNews
Lyra Therapeutics Reports Positive Results From The Enlighten 2 Phase 3 Trial Of Lyr-210 - MarketScreener
Lyra Says Phase 3 Trial of Nasal Implant for Chronic Rhinosinusitis Meets Endpoints - marketscreener.com
Why Is Lyra Therapeutics Stock Surging Over 400% On Monday? - Benzinga
Lyra Therapeutics Announces Positive Phase 3 Trial Results - TipRanks
LYRA Sees Promising Results in ENLIGHTEN 2 Phase 3 Trial for CRS Treatment | LYRA Stock News - GuruFocus
Lyra Therapeutics reports positive phase 3 trial results for CRS treatment - Investing.com Australia
Why Blueprint Medicines Shares Are Trading Higher By 27%; Here Are 20 Stocks Moving Premarket - Benzinga
Lyra Therapeutics stock soars on positive Phase 3 trial results By Investing.com - Investing.com Canada
Lyra Therapeutics stock soars on positive Phase 3 trial results - Investing.com
Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS) - GlobeNewswire
Lyra Therapeutics (NASDAQ:LYRA) Stock Rating Upgraded by Wall Street Zen - Defense World
Lyra Therapeutics Inc (LYRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.68%
0.50%
자본화:
|
볼륨(24시간):